A trial of targeted drugs for chronic myeloid leukaemia when treatment has stopped working (TASTER)
Cancer type:
Status:
Phase:
This trial was for people with chronic myeloid leukaemia. It looked at adding a targeted drug to the targeted drug people were already taking.
It was open to people with chronic myeloid leukaemia (CML):
- whose treatment had stopped working
- that had the
Philadelphia chromosome 
and is in the chronic phase stage or accelerated phase stage
Cancer Research UK supported this trial.
More about this trial
When this trial was done, doctors could treat chronic myeloid leukaemia (CML) with one of the following:
These are cancer growth blockers called tyrosine kinase inhibitors (TKIs). Tyrosine kinase is a protein that acts as a messenger to stimulate cancer cells to grow. TKIs block these messages.
Sometimes these drugs stop working. So researchers were looking for other drugs to help people in this situation. In this trial, they are looked at other TKI's
The aims of this trial were to find out:
- how well adding a newer drug works
- what the side effects are
- how it affects
quality of life
Summary of results
There aren't any results available for this trial. This was because it closed earlier than planned as it was difficult to recruit patients to take part.
Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Chief Investigator
Professor Mhairi Copland
Supported by
Cancer Research UK
University of Glasgow
NHS Greater Glasgow and Clyde
Other information
This is Cancer Research UK trial number CRUK/17/016.
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
